Multimodal treatment combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy and adjuvant therapy for pancreatic neck-body cancer: Case series

Table 3 Postoperative pathology data and follow-up results, n (%)

Characteristic	N = 11
Degree of differentiation
High	2 (18)
Medium	4 (36)
Medium-low	3 (27)
Low	2 (18)
Pathological staging
IA	3 (27)
IB	3 (27)
IIA	1 (9)
IIB	4 (36)
R0 resection
Yes	11 (100)
Lymph node harvest, median (range)	16 (11-25)
Positive lymph node
0	7 (64)
11d	1 (9)
8a	2 (18)
8a/9/14p	1 (9.1)
Nerve invasion	7 (64)
Tumor regression grading
0	1 (9)
1	0 (0)
2	7 (64)
3	3 (27)
Postoperative adjuvant therapy
AG + PD-1	1 (9)
Chemoradiotherapy	4 (36)
Gemcitabine	1 (9)
The mFOLFIRINOX	1 (9)
S-1	4 (36)
Blood glucose level
Normal	4 (36)
Diabetes	5 (46)
Impaired glucose tolerance	2 (18)
Follow-up (months), median (range)	15 (8-33)
Recurrence and metastasis
No	8 (73)
Liver	1 (9)
Local and liver	1 (9)
Local and radial bone	1 (9)
Survival state
Death	1 (9)
Survived with tumor	2 (18)
Tumor-free	8 (73)
Median overall survival (month)	20.5
Median disease-free survival (month)	13.3

AG: Albumin-bound paclitaxel and gemcitabine; PD: Pancreaticoduodenectomy; S-1: Tegafur, gimeracil, and oteracil potassium; mFOLFIRINOX: Modified FOLFIRINOX regimen, including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin.